Fundus fluorescein angiographic assessment of patients with proliferative diabetic retinopathy and macular edema before and after intravitreal injection of Bevacizumab

Simple item page
dc.contributor.authorAnkuren_US
dc.contributor.authorKumar, Yogeshen_US
dc.contributor.authorArora, Deepeshen_US
dc.contributor.authorTyagi, Rupalien_US
dc.contributor.authorMittal, Sanjeev Kumaren_US
dc.date.accessioned2020-11-18T10:00:08Z
dc.date.available2020-11-18T10:00:08Z
dc.date.issued2019-11
dc.description.abstractBackground: To assess the role of intravitreal bevacizumab (1.25 mg) in patients with proliferative diabetic retinopathy with macular edema in terms of change in leakage area and best-corrected visual acuity.Methods: This prospective randomized interventional study was conducted in the Department of Ophthalmology from September 2013 to August 2015 and included thirty eyes of twenty patients.After a detailed history and ocular examination, diagnosed cases of proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME) underwent sequential fundus fluorescein angiography. Bevacizumab was administered intravitreally. Patients were assessed two hours after injection for anterior chamber reaction and intraocular pressure and were advised follow-ups at 24 hours and then at 1, 4, 8 and 12 weeks. For the outcome, the change of retinal new vessels by assessment of leakage area using Quantitative Planimetric Analysis (QPA) of photographs as well as the change in best-corrected visual acuity (BCVA) from baseline to the 12 weeks follow-up, were done. Results were analyzed statistically by applying t-test.Results: Intravitreal bevacizumab injection lead to a significant decrease in leakage in DME and PDR, and improvement in mean BCVA. The effect was maximum at 4 weeks which weaned off as the study progressed through it remains statistically significant at the end of 12 weeks.Conclusions: Intravitreal bevacizumab plays a major role in treating and reducing visual deterioration in patients with proliferative diabetic retinopathy and diabetic macular edema.en_US
dc.identifier.affiliationsDepartment of Ophthalmology Adesh Medical College and Hospital, Mohri, Shahbad, Ambala, Haryana, Indiaen_US
dc.identifier.affiliationsDepartment of Ophthalmology SHKM, Government Medical College, Nuh, Haryana, Indiaen_US
dc.identifier.affiliationsConsultant Amritsar Eye Clinic East Canal Road, Dehradun, Uttarakhand, Indiaen_US
dc.identifier.affiliationsDepartment of Ophthalmology Shri Guru Ram Rai Institute of Medical and Health Sciences Dehradun, Uttarakhand, Indiaen_US
dc.identifier.affiliationsDepartment of Ophthalmology AIIMS, Rishikesh, Uttarakhand, Indiaen_US
dc.identifier.citationAnkur, Kumar Yogesh, Arora Deepesh, Tyagi Rupali, Mittal Sanjeev Kumar. Fundus fluorescein angiographic assessment of patients with proliferative diabetic retinopathy and macular edema before and after intravitreal injection of Bevacizumab. International Journal of Research in Medical Sciences. 2019 Nov; 7(11): 4111-4118en_US
dc.identifier.issn2320-6071
dc.identifier.issn2320-6012
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/211864
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber11en_US
dc.relation.volume7en_US
dc.source.urihttps://dx.doi.org/10.18203/2320-6012.ijrms20194976en_US
dc.subjectDiabetic retinopatthy, Fluoroscien angiography neovasculariztion, Intravitreal bevacizumab, Macular edemaen_US
dc.titleFundus fluorescein angiographic assessment of patients with proliferative diabetic retinopathy and macular edema before and after intravitreal injection of Bevacizumaben_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijrms2019v7n11p4111.pdf
Size:
224.38 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Research in Medical Sciences